A patient-driven clinicogenomic partnership for metastatic prostate cancer.

Journal: Cell Genomics

Molecular profiling studies have enabled discoveries for metastatic prostate cancer (MPC) but have predominantly occurred in academic medical institutions and involved non-representative patient populations. We established the Metastatic Prostate Cancer Project (MPCproject, mpcproject.org), a patient-partnered initiative to involve patients with MPC living anywhere in the US and Canada in molecular research. Here, we present results from our partnership with the first 706 MPCproject participants. While 41% of patient partners live in rural, physician-shortage, or medically underserved areas, the MPCproject has not yet achieved racial diversity, a disparity that demands new initiatives detailed herein. Among molecular data from 333 patient partners (572 samples), exome sequencing of 63 tumor and 19 cell-free DNA (cfDNA) samples recapitulated known findings in MPC, while inexpensive ultra-low-coverage sequencing of 318 cfDNA samples revealed clinically relevant AR amplifications. This study illustrates the power of a growing, longitudinal partnership with patients to generate a more representative understanding of MPC.

Jett Crowdis, Sara Balch, Lauren Sterlin, Beena Thomas, Sabrina Camp, Michael Dunphy, Elana Anastasio, Shahrayz Shah, Alyssa Damon, Rafael Ramos, Delia Sosa, Ilan Small, Brett Tomson, Colleen Nguyen, Mary Mcgillicuddy, Parker Chastain, Meng He, Alexander T Cheung, Stephanie Wankowicz, Alok Tewari, Dewey Kim, Saud Aldubayan, Ayanah Dowdye, Benjamin Zola, Joel Nowak, Jan Manarite, Idola Gunn, Bryce Olson, Eric Lander, Corrie Painter, Nikhil Wagle, Eliezer Van Allen
Relevant Conditions

Prostate Cancer